|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/21 Y-mAbs Therapeutics, Inc. 10-K 12/31/20 84:9.6M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.62M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 45K
3: EX-21.1 Subsidiaries List HTML 23K
4: EX-23 Consent of Expert or Counsel HTML 23K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 26K
8: EX-32.2 Certification -- §906 - SOA'02 HTML 26K
15: R1 Document and Entity Information HTML 87K
16: R2 Consolidated Balance Sheets HTML 95K
17: R3 Consolidated Balance Sheets (Parenthetical) HTML 36K
18: R4 Consolidated Statements of Net Loss and HTML 70K
Comprehensive Loss
19: R5 Consolidated Statements of Changes in HTML 68K
Stockholders' Equity
20: R6 Consolidated Statements of Cash Flows HTML 90K
21: R7 Organization and Description of Business HTML 27K
22: R8 Basis of Presentation HTML 31K
23: R9 Summary of Significant Accounting Policies HTML 104K
24: R10 Net Loss Per Share HTML 43K
25: R11 Accrued Liabilities HTML 43K
26: R12 License Agreements and Commitments HTML 161K
27: R13 Stockholders' Equity HTML 32K
28: R14 Share-Based Compensation HTML 101K
29: R15 Related Party Transactions HTML 27K
30: R16 Income Taxes HTML 90K
31: R17 Other Benefits HTML 26K
32: R18 Subsequent Events HTML 27K
33: R19 Quarterly Consolidated Financial Data (Unaudited) HTML 76K
34: R20 Summary of Significant Accounting Policies HTML 145K
(Policies)
35: R21 Summary of Significant Accounting Policies HTML 69K
(Tables)
36: R22 Net Loss Per Share (Tables) HTML 41K
37: R23 Accrued Liabilities (Tables) HTML 42K
38: R24 License Agreements and Commitments (Tables) HTML 149K
39: R25 Share-Based Compensation (Tables) HTML 98K
40: R26 Income Taxes (Tables) HTML 88K
41: R27 Quarterly Consolidated Financial Data (Unaudited) HTML 75K
(Tables)
42: R28 BASIS OF PRESENTATION - Accumulated deficit and HTML 30K
cash (Details)
43: R29 BASIS OF PRESENTATION - Secondary public offering HTML 38K
(Details)
44: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 42K
Value Measurement (Details)
45: R31 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K
Operating Leases (Details)
46: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 35K
Property and Equipment (Details)
47: R33 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 25K
Income Taxes (Details)
48: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 54K
Revenue Recognition (Details)
49: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 32K
Research and development (Details)
50: R36 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Other HTML 31K
policies (Details)
51: R37 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 55K
Recently issued accounting pronouncements
(Details)
52: R38 NET LOSS PER SHARE - Basic and diluted (Details) HTML 38K
53: R39 NET LOSS PER SHARE - Anti-dilutive securities HTML 26K
(Details)
54: R40 Accrued Liabilities (Details) HTML 36K
55: R41 LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and HTML 54K
MabVax License Agreement (Details)
56: R42 LICENSE AGREEMENTS AND COMMITMENTS - SADA License HTML 95K
Agreement (Details)
57: R43 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 44K
agreements (Details)
58: R44 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 64K
agreements (Details)
59: R45 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 33K
(Details)
60: R46 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 41K
maturities (Details)
61: R47 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 28K
and discount rate (Details)
62: R48 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 42K
Preferred Stock (Details)
63: R49 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 70K
non-employees, Stock (Details)
64: R50 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 46K
(Details)
65: R51 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 34K
66: R52 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 44K
67: R53 SHARE-BASED COMPENSATION - Stock option expense HTML 41K
(Details)
68: R54 SHARE-BASED COMPENSATION - Stock Option Valuation HTML 42K
(Details)
69: R55 SHARE-BASED COMPENSATION - Stock option activity HTML 64K
(Details)
70: R56 SHARE-BASED COMPENSATION - Stock option HTML 31K
unrecognized compensation (Details)
71: R57 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 59K
Activity (Details)
72: R58 Related Party Transactions (Details) HTML 37K
73: R59 INCOME TAXES - Expense (Details) HTML 42K
74: R60 INCOME TAXES - Reconciliation of Income Taxes HTML 48K
(Details)
75: R61 INCOME TAXES - Deferred tax assets/(Liabilities) HTML 52K
(Details)
76: R62 INCOME TAXES - Uncertain tax positions (Details) HTML 25K
77: R63 INCOME TAXES - Net Operating Loss Carryforwards HTML 39K
(Details)
78: R64 Other Benefits (Details) HTML 25K
79: R65 Subsequent Events (Details) HTML 51K
80: R66 Quarterly Consolidated Financial Data (Unaudited) HTML 47K
(Details)
82: XML IDEA XML File -- Filing Summary XML 150K
14: XML XBRL Instance -- ymab-20201231x10k_htm XML 1.69M
81: EXCEL IDEA Workbook of Financial Reports XLSX 100K
10: EX-101.CAL XBRL Calculations -- ymab-20201231_cal XML 139K
11: EX-101.DEF XBRL Definitions -- ymab-20201231_def XML 545K
12: EX-101.LAB XBRL Labels -- ymab-20201231_lab XML 1.22M
13: EX-101.PRE XBRL Presentations -- ymab-20201231_pre XML 984K
9: EX-101.SCH XBRL Schema -- ymab-20201231 XSD 169K
83: JSON XBRL Instance as JSON Data -- MetaLinks 338± 512K
84: ZIP XBRL Zipped Folder -- 0001558370-21-002172-xbrl Zip 733K
EXHIBIT 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Bo Kruse, certify that:
| 1. | I have reviewed this Annual Report on Form 10-K of Y-mAbs Therapeutics, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| |
Date: March 1, 2021 | |
| /s/ Bo Kruse |
| Name: Bo Kruse |
| Title: EVP, Chief Financial Officer |
| (Principal Financial Officer) |
1
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/1/21 | 4 | ||
| For Period end: | 12/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/19/21 Y-mAbs Therapeutics, Inc. 8-K:7,8,9 2/17/21 15:2.7M Toppan Merrill/FA 12/22/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 12/17/20 11:674K Toppan Merrill/FA 11/05/20 Y-mAbs Therapeutics, Inc. 10-Q 9/30/20 68:6.7M Toppan Merrill Bridge/FA 10/08/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 10/07/20 11:294K Toppan Merrill/FA 4/21/20 Y-mAbs Therapeutics, Inc. 8-K:1,9 4/15/20 2:348K Toppan Merrill/FA 12/19/19 Y-mAbs Therapeutics, Inc. 8-K:1,9 12/13/19 3:170K Toppan Merrill/FA 9/19/19 Y-mAbs Therapeutics, Inc. 8-K:1,9 9/13/19 2:129K Toppan Merrill/FA 9/07/18 Y-mAbs Therapeutics, Inc. S-1/A 5:4.4M Toppan Merrill-FA 8/24/18 Y-mAbs Therapeutics, Inc. S-1 31:12M Toppan Merrill-FA |